BioSpace News Archive

Emergent BioSolutions Inc. (NYSE: EBS) today reported selected financial results for the third quarter ended September 30, 2023.

WuXi AppTec received the 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan, a growth advisory & growth opportunity analytics firm.

SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, today reported third quarter 2023 financial results and recent portfolio updates.

Eli Lilly and Company announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares of common stock of POINT Biopharma Global Inc., for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today provides a business update and announces financial results for the quarter ended September 30, 2023.

Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) announced third quarter financial results for the period ended September 30, 2023, and reviewed recent accomplishments.